Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glioblastoma Clear all
Not listed Phase 1 Interventional

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

NCT04642937
View directory record Official record
Conditions
Glioblastoma
Interventions
Treatment with hP1A8
Drug
Lead sponsor
OX2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Sep 28, 2026, 11:52 PM EDT
Available No phase listed Expanded access

BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast

NCT04091295
View directory record Official record
Conditions
Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma, Soft Tissue Sarcoma, Chordoma, Sarcoma, Carcinoma of Breast, Single Patient IND for Glioblastoma, Ovarian Carcinoma, Non-small Cell Lung Cancer , Prostate Cancer
Interventions
DNG64-CAR-V
Drug
Lead sponsor
Aveni Foundation
Other
Eligibility
12 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 28, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional

A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors

NCT01351519
View directory record Official record
Conditions
Malignant Glioma, Glioma, Glioblastoma, Glioblastoma Multiforme, Astrocytoma
Interventions
Aminolevulinic Acid
Drug
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 28, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

NCT01349036
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
PLX3397
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 28, 2026, 11:52 PM EDT
Recruiting Not applicable Interventional

Serial MRI Scans During Radiation Therapy

NCT04188535
View directory record Official record
Conditions
Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions
MRI IMAGING
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 11:52 PM EDT
Recruiting Phase 3 Interventional

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

NCT07461948
View directory record Official record
Conditions
Glioblastoma
Interventions
Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging, Electronic Health Record Review, Ferumoxytol, Magnetic Resonance Imaging
Procedure · Other · Drug + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 28, 2026, 11:52 PM EDT
Active, not recruiting Phase 2 Interventional

Surgical Pembro +/- Olaparib w TMZ for rGBM

NCT05463848
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
Pembrolizumab, Olaparib, Temozolomide
Drug
Lead sponsor
L. Nicolas Gonzalez Castro, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma

NCT00525525
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Bevacizumab, Tarceva, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 28, 2026, 11:52 PM EDT
Terminated Not applicable Interventional Results available

Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma

NCT02039778
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma
Interventions
Stem Cell Radiotherapy (ScRT) and Temozolomide
Radiation
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 28, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

NCT05267106
View directory record Official record
Conditions
Glioblastoma, Adult-type Diffuse Gliomas
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
32
States / cities
Beverly Hills, California • Duarte, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 3 Interventional

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

NCT03776071
View directory record Official record
Conditions
Glioblastoma
Interventions
Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy
Drug · Other · Radiation
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

NCT03684811
View directory record Official record
Conditions
Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas), Cohort 3a and 3b: Chondrosarcoma, Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma, Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Interventions
FT-2102, Azacitidine, Nivolumab, Gemcitabine and Cisplatin
Drug · Biological
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Gilbert, Arizona • Aurora, Colorado • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

NCT04716699
View directory record Official record
Conditions
Glioblastoma
Interventions
Biospecimen Collection, Lidocaine, Resection
Procedure · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00003409
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2009 · Synced Sep 28, 2026, 11:52 PM EDT
Not listed Phase 2 Interventional

A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT01403311
View directory record Official record
Conditions
Glioma
Interventions
5-Aminolevuline Acid
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 25, 2014 · Synced Sep 28, 2026, 11:52 PM EDT
Suspended Phase 1 Interventional

Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)

NCT04222309
View directory record Official record
Conditions
Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer
Interventions
Laparoscopically harvested omental free flap
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 28, 2026, 11:52 PM EDT
Terminated Phase 2 Interventional Results available

Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma

NCT02395692
View directory record Official record
Conditions
Adult Brain Glioblastoma
Interventions
Treatment, Methoxyamine, Temozolomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 2 Interventional

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406
View directory record Official record
Conditions
Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue, Nervous System Diseases
Interventions
DNX-2401, pembrolizumab
Biological
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 28, 2026, 11:52 PM EDT
Withdrawn Phase 2 Interventional

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

NCT03014804
View directory record Official record
Conditions
Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma, Recurrent Glioblastoma, Small Cell Glioblastoma
Interventions
autologous dendritic cells pulsed with tumor lysate antigen Vaccine, Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Biological · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00068510
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 2 Interventional

Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00099125
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
118
States / cities
Phoenix, Arizona • Burbank, California • Fresno, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 2 Interventional Results available

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

NCT00979017
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
Avastin, Temozolomide, Irinotecan
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 28, 2026, 11:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas

NCT00042991
View directory record Official record
Conditions
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma, Untreated Childhood Glioblastoma, Untreated Childhood Gliomatosis Cerebri, Untreated Childhood Gliosarcoma, Untreated Childhood Oligodendroglioma
Interventions
gefitinib, radiation therapy, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 21 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 28, 2026, 11:52 PM EDT
Active, not recruiting Phase 1 Interventional Results available

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

NCT02852655
View directory record Official record
Conditions
Brain Cancer
Interventions
MK-3475
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 28, 2026, 11:52 PM EDT